Skip to main content
×
×
Home

Inference and suggestion in a clinical trial (Niamid in Mongolism)

  • W. A. Heaton-Ward (a1)
Extract

At the International Symposium on Niamid (nialamide)—1-/21—(benzylcarbamyl) ethyl/2-iso-nicotinoyl hydrazine—a mono-amine oxidase inhibitor, held in Lisbon in November, 1959, T. S. Davies reported that a 35-year-old mongol of imbecile grade, who had previously been inert and who had never spoken, gradually began to speak in monosyllables and, after two months on the drug, was able to converse in short sentences, showed increased physical activity and was able to undertake simple domestic tasks. It is not clear exactly what dosage of Niamid this patient received, but it was within the range of 30 mgm to 75 mgm daily. This report received wide publicity, out of its context, in the lay press, with its inevitable tendency to give the impression that a treatment of mongolism had been discovered, an impression which it is perhaps unnecessary to say Davies had certainly not intended to give.

Copyright
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: -
  • EISSN: 2514-9946
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 2 *
Loading metrics...

Abstract views

Total abstract views: 7 *
Loading metrics...

* Views captured on Cambridge Core between 8th February 2018 - 12th June 2018. This data will be updated every 24 hours.

Inference and suggestion in a clinical trial (Niamid in Mongolism)

  • W. A. Heaton-Ward (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *